Xavier Pedro Luiz Porfirio, Müller Susanne, Fukumasu Heidge
Laboratory of Comparative and Translational Oncology (LOCT), Department of Veterinary Medicine, Faculty of Animal Science and Food Engineering, University of Sao Paulo, Pirassununga, Brazil.
Structural Genomics Consortium and Institute of Pharmaceutical Chemistry, Buchmann Institute for Molecular Life Sciences, Johann Wolfgang Goethe University, Frankfurt am Main, Germany.
Front Oncol. 2020 Oct 23;10:591843. doi: 10.3389/fonc.2020.591843. eCollection 2020.
A plethora of data has highlighted the role of epigenetics in the development of cancer. Initiation and progression of different cancer types are associated with a variety of changes of epigenetic mechanisms, including aberrant DNA methylation, histone modifications, and miRNA expression. At the same time, advances in the available epigenetic tools allow to investigate and reverse these epigenetic changes and form the basis for the development of anticancer drugs in human oncology. Although human and canine cancer shares several common features, only recently that studies emerged investigating the epigenetic landscape in canine cancer and applying epigenetic modulators to canine cancer. This review focuses on the existing studies involving epigenetic changes in different types of canine cancer and the use of small-molecule inhibitors in canine cancer cells.
大量数据凸显了表观遗传学在癌症发展中的作用。不同癌症类型的起始和进展与表观遗传机制的多种变化相关,包括异常的DNA甲基化、组蛋白修饰和miRNA表达。同时,现有表观遗传工具的进展使得研究和逆转这些表观遗传变化成为可能,并为人肿瘤学中抗癌药物的开发奠定了基础。尽管人类癌症和犬类癌症有一些共同特征,但直到最近才有研究开始探究犬类癌症的表观遗传格局,并将表观遗传调节剂应用于犬类癌症。本综述重点关注涉及不同类型犬类癌症表观遗传变化的现有研究以及小分子抑制剂在犬类癌细胞中的应用。